A French National Survey on Clotting Disorders in Mastocytosis

Ana B Carvalhosa1, Achille Aouba, Gandhi Damaj

  • 1From the French Reference Centre for Mastocytosis (CEREMAST), Necker Children's Hospital, Assistance Publique - Hôpitaux de Paris (APHP), France (ABC, GD, DC, CB, SB, LF, OL, OH, M-OC); Haemostasis and Thrombosis Unit, Haemophilia Clinic, Division of Haematology, St-Luc University Hospital, Brussels, Belgium (ABC, CH); Department of Internal Medicine, Caen University Hospital, France (AA); Department of Haematology, Caen University Hospital, France (GD); Department of Pathology, Necker Children's Hospital, APHP, France (DC); Department of Biological Haematology, Necker Children's Hospital, APHP, France (CB); Department of Haematology and Cell Therapy, Tours University Hospital, France (EG); Department of Internal and Vascular Medicine, Lyon Sud University Hospital, France (SD, ID); Department of Internal Medicine, Saint-Etienne University Hospital, France (PC); Department of Internal Medicine, Cochin Hospital, APHP, France (NC-C); Department of Internal Medicine, Lille University Hospital, France (DL); Infectious Diseases Department, Necker Children's Hospital, APHP, France (BP, OL); Department of Dermatology, Tenon University Hospital, APHP, France (SB); Department of Haematology, Necker Children's Hospital, APHP, France (LF, OH, M-OC); and Sorbonne Paris Cité, Paris Descartes University, Imagine Institute, Paris, France (LF, OL, OH, M-OC).

Medicine
|October 9, 2015
PubMed

Insights

Mastocytosis patients can experience clotting issues due to mast cell degranulation and infiltration. Steroids effectively manage these bleeding disorders by inhibiting mast cell activity, unlike traditional treatments.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Mastocytosis involves clonal mast cell proliferation, organ infiltration, and degranulation.
  • Clotting abnormalities are observed in some mastocytosis patients but are poorly understood.
  • Mast cell mediators like heparin and tryptase can impact hemostasis.

Purpose of the Study:

  • To investigate the characteristics and management of clotting abnormalities in mastocytosis patients.
  • To identify the underlying mechanisms of hemostatic disorders in mastocytosis.
  • To evaluate the efficacy of different management strategies for bleeding complications.

Main Methods:

  • Retrospective analysis of 14 adult mastocytosis patients with clotting abnormalities.
  • Utilized the French Reference Centre for Mastocytosis database.
  • Assessed primary and secondary hemostasis disorders, bleeding characteristics, and treatment outcomes.

Main Results:

  • Four patients had primary hemostasis disorders, and 10 had secondary hemostasis impairment.
  • Seven patients experienced bleeds characteristic of coagulation cascade disorders (5 severe/life-threatening).
  • Conventional hemostatic management was unsuccessful; steroids inhibiting mast cell activity were effective.
  • Aggressive mastocytosis and increased mortality were noted in patients with secondary hemostasis disorders.

Conclusions:

  • Mast cell degranulation and high tumor burden induce pro-coagulant and anti-coagulant states.
  • These states lead to a spectrum of bleeding complications, from asymptomatic to life-threatening.
  • Effective hemostatic control in mastocytosis is achieved through mast cell inhibitors, particularly steroids.

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.9K
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.4K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.8K